Canada’s life sciences industry split on Canada-EU free trade agreement
Rx&D, BIOTECanada say intellectual property proposals will protect Canadian innovation and attract capital, but harmonization with EU could put generic drug and regenerative medicine industries at a disadvantage.
SPONSORED CONTENT
Get Tuesdays: Innovation & Industry Newsletter
The policies, decisions, and people working on investment and regulation in the industry and innovation realm.
By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy
